Cornell researchers have developed a new vaccine platform that could provide more robust, longer-lasting protection from both ...

Alignment with National Health Security Goals: GeoVax’s focus on U.S.-based vaccine production supports HHS’s priority of reducing dependency on foreign pharmaceutical supply chains, ensuring ...

The ChAdOx1 viral vector was developed at the University of Oxford and has been investigated as a potential vector for ...

The Global Viral Vector Market was valued at approximately USD 3.10 billion in 2022 and is projected to grow at a robust CAGR of more than 11.5% during the forecast period 2023-2030. Read the Market ...

The global viral vector and plasmid DNA manufacturing market size is calculated at USD 8.66 billion in 2025 and is expected ...

Toxoid vaccines are made with inactivated toxins produced by a pathogen, such as tetanus, rather than the pathogen itself. Viral vector vaccines are similar to mRNA vaccines but are housed within ...

It is a good idea to leave them unpruned over winter: they provide food and shelter for wildlife and can look attractive even in decay, particularly when sprinkled with frost on cold mornings ...

Kennedy Jr., has a long history of raising doubts about vaccines — despite decades of evidence showing they've saved millions of people from debilitating illness or death. "People forget what it ...

Robert F. Kennedy Jr. is head­ed for Sen­ate con­fir­ma­tion fol­low­ing Tues­day’s com­mit­tee vote and a state­ment of sup­port from the GOP’s biggest skep­tic.

Viral vectors used in vaccines do not affect or interact with your DNA. The tough protein coat of the adenovirus helps protect the DNA genetic instructions inside. As a result, viral vector vaccines ...

The other COVID-19 vaccines authorised for use in the EU are mRNA vaccines (Pfizer/BioNTech and Moderna) or viral vector vaccines (AstraZeneca and Janssen).

Image credit: Shutterstock/Tada Images. Thermo Fisher is cutting the headcount at two of its US facilities by 300 as the company continues to overhaul its viral vector manufacturing output.